Literatur

Autor(en) Titel Quelle Links
Eber S Angeborene Erythrozytenmembrandefekte. In: Gadner, H, Gaedicke, G, Niemeyer, C, Ritter, J (Hrsg.): Pädiatrische Hämatologie und Onkologie 2006, 125    
Ebell W Hämatopoetische Stammzelltransplantation. in: Gadner H, Gaedicke G, Niemeyer CH, Ritter J:. Pädiatrische Hämatologie und Onkologie Springer-Verlag, 2006, 66    
Eber S Leitlinie der Gesellschäft für Pädiatrische Onkologie und Hämatologie Hereditäre Sphärozytose.    
Eckert C, Landt O, Taube T, Seeger K, Beyermann B, Proba J, Henze G Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2000, 14: 316    
Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, Pogodda M, Proba J, Henze G Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001, 358: 1239    
Eckert C, Einsiedel HG, Hartmann R, von Stackelberg A, Volpel S, Guggemos A, Hanzsch N, Kawan L, Seeger K, Henze G Clonal stability of initial leukemia in a child with CNS relapse 7. 4 years after bone marrow relapse of common acute lymphoblastic leukemic. haematologica 2004, 89:ECR23.    
Eckert C, Flohr T, Koehler R, Hagedorn N, Moericke A, Stanulla M, Kirschner-Schwabe R, Cario G, Stackelberg A, Bartram CR, Henze G, Schrappe M, Schrauder A Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. Leukemia 2011, May, Epub ahead of print    
Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. European journal of cancer 2013, 49: 1346    
Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Schrauder A, Escherich G, Sramkova L, Niggli F, Hitzler J, von Stackelberg A Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. Journal of clinical oncology 2013, 31: 2736    
Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, Bourquin JP, Klingebiel T, Borkhardt A, Cario G, Alten J, Escherich G, Astrahantseff K, Seeger K, Henze G, von Stackelberg A Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia 2015, 29: 1648    
Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, Hagedorn N, Chen-Santel C, Bader P, Borkhardt A, Cario G, Escherich G, Panzer-Grümayer R, Astrahantseff K, Eggert A, Sramkova L, Attarbaschi A, Bourquin JP, Peters C, Henze G, von Stackelberg A, ALL-REZ BFM Trial Group Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. Journal of clinical oncology 2019 Dec 20; 37: 3493    
Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, Hagedorn N, Chen-Santel C, Bader P, Borkhardt A, Cario G, Escherich G, Panzer-Grümayer R, Astrahantseff K, Eggert A, Sramkova L, Attarbaschi A, Bourquin JP, Peters C, Henze G, von Stackelberg A, ALL-REZ BFM Trial Group Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. Journal of clinical oncology 2019 Dec 20; 37: 3493    
Eden T, Pui C, Schrappe M, Tognoni G, Masera G All children have a right to full access to treatment for cancer. Lancet 2004, 364: 1121    
Effinger KE, Migliorati CA, Hudson MM, McMullen KP, Kaste SC, Ruble K, Guilcher GM, Shah AJ, Castellino SM Oral and dental late effects in survivors of childhood cancer: a Children's Oncology Group report. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2014, 22: 2009    
Egeler RM, Pritchard J, Gadner H, D'Angio GJ An international histiocytic language. Blood 1995, 85: 2281    
Eggert A Pädiatrische Onkologie - ein Überblick. Onkologie heute 07/2016, 48    
Eggert A, Zimmermann M Konzepte klinischer Studien. In: Niemeyer C, Eggert A (Hrsg.): Pädiatrische Hämatologie und Onkologie Springer Verlag GmbH Deutschland 2018, 257    
Eggert A, Simon T, Hero B, Lode H, Ladenstein R, Fischer M, Berthold F Neuroblastom. in: Niemeyer C, Eggert A (Hrsg.): Pädiatrische Hämatologie und Onkologie Springer Verlag GmbH GDeutschland 2006, 2018, 2. vollständig überarbeitete Auflage 2018, 420    
Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N, Zwaan CM, Reinhardt K, Hollink IH, Klusmann JH, Lehrnbecher T, Roettgers S, Stary J, Dworzak M, Welte K, Creutzig U, Reinhardt D Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated With a Higher Incidence of Relapse. Journal of clinical oncology 2010, 28: 2591    
Ehl S, Bogdan C, Niehues T, Borchard G, Baumann U, Hecht J, Koch j, Neubert J, Wiese-Pochelt K, Zepp F Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen.(II) Impfen bei 1. Primären Immundefekterkrankungen und 2. HIV-Infektion. Bundesgesundheitsblatt 2018, 61: 1034    
Eich H, Hero B, Staar S, Micke O, Seegenschmiedt H, Mattke A, Berthold F, Muller R Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma. Strahlenther Onkol 2003, 179: 233    
Eich HT, Muller RP, Micke O, Kocher M, Berthold F, Hero B Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment? Strahlentherapie und Onkologie 2005, 181: 378    
Eichenmüller M, von Schweinitz D, Kappler R Betulinic acid treatment promotes apoptosis in hepatoblastoma cells. International journal of oncology 2009, 35: 873    
Eichenmüller M, Gruner I, Hagl B, Häberle B, Müller-Höcker J, von Schweinitz D, Kappler R Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009, 49: 482    
Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hahlen K, Göbel U, Klingebiel T, Ludwig WD, Henze G Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. Journal of clinical oncology 2005, 23: 7942    
Ejeskar K, Sjoberg R, Abel F, Kogner P, Ambros P, Martinsson T Fine mapping of a tumour suppressor candidate gene region in 1p36. 2-3, commonly deleted in neuroblastomas and germ cell tumours. Med Pediatr Oncol 2001, 36: 61    
El-Ayadi M, Ansari M, Sturm D, Gielen GH, Warmuth-Metz M, Kramm CM, von Bueren AO High-grade glioma in very young children: a rare and particular patient population. Oncotarget 2017 Sep 8; 8: 64564    
Eleftheriou A About Thalassemia - English. Thalassemia International Federation Publications 2007    
Eleftheriou A About Thalassemia - German. Thalassemia International Federation Publications 2015    
Ellinghaus E, Stanulla M, Richter G, Ellinghaus D, Te Kronnie G, Cario G, Cazzaniga G, Horstmann M, Panzer Grümayer R, Cavé H, Trka J, Cinek O, Teigler-Schlegel A, Elsharawy A, Häsler R, Nebel A, Meissner B, Bartram T, Lescai F, Franceschi C, Giordan M, Nürnberg P, Heinzow B, Zimmermann M, Schreiber S, Schrappe M, Franke A Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia 2012, 26: 902    
Elmariah H, Garrett ME, De Castro LM, Jonassaint J, Ataga KI, Eckman J, Ashley-Koch AE, Telen MJ Factors Associated with Survival in a Contemporary Adult Sickle Cell Disease Cohort. American journal of hematology 2014, E-pub ahead of print    
Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sandercock P, Hacke W, Stroke Thrombolysis Trialists' Collaborative Group Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014, 384: 1929    
Emmrich S, Rasche M, Schöning J, Reimer C, Keihani S, Maroz A, Xie Y, Li Z, Schambach A, Reinhardt D, Klusmann JH miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signaling. Genes Dev 2014, 28: 858    
Emmrich S, Streltsov A, Schmidt F, Thangapandi VR, Reinhardt D, Klusmann JH LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia. Mol Cancer 2014, 13: 171    
Encke A, Haas S, Kopp I et al. S3-Leitlinie Prophylaxe der venösen Thrombose (VTE). AWMF Leitlinien-Register Nr. 003/001 2015    
Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, Seddon J, Tarbell N, Boice JD Jr Mortality from second tumors among long-term survivors of retinoblastoma. Journal of the National Cancer Institute 1993, 85: 1121    
US Environmental Protection Agency Office of Radiation and Indoor Air EPA Radiogenic Cancer Risk Models and Projections for the U. S. Population. December 2008    
Erb N, Harms D, Janka-Schaub G Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998, 42: 266    
Erb N, Haverland U, Harms D, Escherich G, Janka-Schaub G High-performance liquid chromatographic assay of metabolites of thioguanine and mercaptopurine in capillary blood. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 796: 87    
Eriksson T, Frisk T, Gray S, von Schweinitz D, Pietsch T, Larsson C, Sandstedt B, Ekstrom T Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma. Exp Cell Res 2001, 270: 88    
Erttmann R, Tafese T, Berthold F, Kerbl R, Mann J, Parker L, Schilling F, Ambros P, Christiansen H, Favrot M, Kabisch H, Hero B, Philip T 10 years' neuroblastoma screening in Europe. Eur J Cancer 1998, 34: 1391    
Escherich G, Göbel U, Jorch N, Spaar HJ, Janka-Schaub GE Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. Klinische Padiatrie 2007, 219: 134    
Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE, COALL study group Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia : 2010, 24: 298    
Escherich G, Troeger AF, Göbel U, Graubner U, Pekrun A, Jorch N, Kaspers G, Zimmermann M, Zur Stadt U, Kazemir K, Pieters R, Horstmann M, Denboer ML, Janka-Schaub G The long-term impact of in vitro drug sensitivity testing on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 2011, Epub ahead of print    
Escherich G, Zimmermann M, Janka-Schaub G, CoALL study group Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. Pediatric blood & cancer 2013, 60: 254    
Escherich G, Schrappe M, Creutzig U Akute lymphoblastische Leukämie (ALL) im Kindesalter. AWMF online 2016    
Eselgrim M, Grunert H, Kuhne T, Zoubek A, Kevric M, Burger H, Jürgens H, Mayer-Steinacker R, Gosheger G, Bielack SS Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatric blood & cancer 2005,    
Escherich G, Zur Stadt U, Zimmermann M, Horstmann MA, on behalf of the CoALL study group Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial. British journal of haematology 2013, epub ahead of print    
Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006 May 1; 107: 3469    
Eveslage M, Calaminus G, Warmuth-Metz M, Kortmann, RD, Pohl F, Timmermann B, Schuhmann MU, Flitsch J, Faldum A, Müller HL Postoperative Lebensqualität bei Kindern und Jugendlichen mit Kraniopharyngeom. Dtsch Arztebl Int 2019, 116: 321    
Exner M, Engelhart S, Gebel J, Ilschner C, Pfeiffer R, Höller C, Dilloo D, Maschmeyer G, Simon A Hygiene-Tipps für immunsupprimierte Patienten zur Vermeidung übertragbarer Infektionskrankheiten. Hyg Med 2011, 36 – 1/2    
Eyrich M Immuntherapie rezidivierter Gliome – ein individualisierter Therapieansatz. WiR - die Zeitschrift der Deutschen Leukämie-Forschungshilfe e.V. und der Deutschen Kinderkrebsstiftung 2/2018    
52 items found

Die Literatur-Datenbank ist alphabetisch nach dem Namen des Erstautors sortiert - bitte anklicken. Sie umfasst alle Angaben, die im Laufe der letzten Jahre von den Studienzentralen ausgewählt wurden oder die in diesem Informationsangebot referenziert werden, zum Beispiel in den Patienteninformationstexten.